Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 59, Number 5, September 10, 2002
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, A. B.
Right arrow Articles by Frank, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, A. B.
Right arrow Articles by Frank, J. A.
Related Collections
Right arrow All Imaging
Right arrow MRI
Right arrow Volumetric MRI
Right arrow Multiple sclerosis

Neurology 2002;59:688-694
© 2002 American Academy of Neurology

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNß-1b

A. B. Rao, MD, N. Richert, PhD, MD, T. Howard, BS, B.K. Lewis, BA, C.N. Bash, MD, H.F. McFarland, MD and J. A. Frank, MD

From the Laboratory of Diagnostic Radiology Research, Clinical Center (Drs. Rao, Richert, Bash, and Frank, T. Howard, and B. Lewis), Neuroimmunology Branch National Institutes of Neurological Diseases and Stroke (Dr. McFarland), NIH, Bethesda, MD; and Department of Radiology (Dr. Rao), Stanford University, CA.

Address correspondence and reprint requests to Dr. Joseph A. Frank, Laboratory of Diagnostic Radiology Research, Building 10 Room B1N256, 10 Center Drive MSC 1074, Bethesda, MD 20892-1074; e-mail: jafrank{at}helix.nih.gov

Objective: To determine the effect of IV methylprednisolone (IVMP) on brain fraction volume (BFV), contrast-enhancing (CE) lesions, and white matter lesion load (WMLL) in patients with relapsing-remitting MS treated for acute exacerbations.

Background: MRI metrics of MS disease activity are being used as outcome measures in early phase treatment trials, however the short-term effects of IVMP treatment on cerebral atrophy are unknown.

Methods: Serial monthly MRI were performed in 26 patients enrolled in a baseline vs treatment trial with interferon ß-1b (IFNß-1b) who were followed for 3 months before and after IVMP. All 26 patients were evaluated while receiving IFNß-1b, and 12 patients were also studied during the baseline stage of the trial (NHx). Acute exacerbations were treated with IVMP (1 g/d) for 3 to 5 days. Precontrast and postcontrast T1-weighted and proton density T2-weighted fast spin-echo images were analyzed.

Results: Fifty-six acute exacerbations were evaluated. For the 3 months before IVMP, there was no difference in WMLL or BFV compared to month IVMP was administered. There was a significant decrease in BFV at month 1 after IVMP in the IFNß-1b and NHx groups. Compared to the month IVMP was administered, there was a difference in the CE lesions for months -3 and -1 prior (p < 0.039) in NHx patients. Following IVMP, CE lesions decreased (p < 0.0004) for months 1, 2, and 3 in both groups, but there was no effect on WMLL.

Conclusions: BFV and CE lesions were significantly decreased for 1 month (BFV) and 3 months (CE lesions) following IVMP. Therefore, MRI studies should be delayed by probably at least 2 months following IVMP to avoid a possible confounding steroid effect in a clinical trial.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. R. Altmann, B. Jasperse, F. Barkhof, K. Beckmann, M. Filippi, L. D. Kappos, P. Molyneux, C. H. Polman, C. Pozzilli, A. J. Thompson, et al.
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
Neurology, February 17, 2009; 72(7): 595 - 601.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Neurology, July 8, 2008; 71(2): 136 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al.
I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy
Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. H. Miller, D. Soon, K. T. Fernando, D. G. MacManus, G. J. Barker, T. A. Yousry, E. Fisher, P. W. O'Connor, J. T. Phillips, C. H. Polman, et al.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
Neurology, April 24, 2007; 68(17): 1390 - 1401.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
F.G. Garaci, V. Colangelo, A. Ludovici, F. Gaudiello, S. Marziali, D. Centonze, L. Boffa, G. Simonetti, and R. Floris
A Diffusion Longitudinal MR Imaging Study in Normal-Appearing White Matter in Untreated Relapsing-Remitting Multiple Sclerosis
AJNR Am. J. Neuroradiol., March 1, 2007; 28(3): 475 - 478.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Neurology, September 26, 2006; 67(6): 944 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
Y. Ge
Multiple Sclerosis: The Role of MR Imaging
AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1165 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. D. Richert, T. Howard, J. A. Frank, R. Stone, J. Ostuni, J. Ohayon, C. Bash, and H. F. McFarland
Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis
Neurology, February 28, 2006; 66(4): 551 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
S. C.A. Steens, G. M. Steup-Beekman, G. P.Th. Bosma, F. Admiraal-Behloul, H. Olofsen, J. Doornbos, T. W.J. Huizinga, and M. A. van Buchem
The Effect of Corticosteroid Medication on Quantitative MR Parameters of the Brain
AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2475 - 2480.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
Multiple Sclerosis, April 1, 2005; 11(2): 140 - 145.
[Abstract] [PDF]

Home page
 NeurologyHome page
W. H. Stuart and P. Vermersch
Concomitant therapy for multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34.
[Abstract] [Full Text]

Home page
 NeurologyHome page
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland
Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients
Neurology, March 9, 2004; 62(5): 719 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans-Coutinho, M. Clanet, E. W. Radue, and L. Kappos
Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple Sclerosis
Arch Neurol, December 1, 2003; 60(12): 1736 - 1739.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.